Ch 7: neoplasia Flashcards

1
Q

desmoplasia

A

abundant collagenous stroma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

scirrhous

A

desmoplastic tumors that are stony and hard

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

adenoma

A

• Adenoma is used for benign epithelial neoplasm derived from glands

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

papilloma

A

= benign epithelial neoplasms producing microscopically visible finger-like or warty projections from endothelial cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

cystadenoma

A

adenomas that form large cystic masses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

polyp

A

when a neoplasm benign or malignant produces a macroscopically visible projection above the mucosal surface and projects into the lumen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

sarcoma

A

are malignant tumors that arise from mesenchymal tissue
o sar means fleshy: they have little CT stroma
o ex. fibrosarcoma, chondrosarcome, leiomyosarcoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

carcinomas

A

carcinomas are malignant neoplasms of epithelial cell origin, derived from any of the three layers
o ex. squamous cell carcinoma,
o adenocarcinoma: lesion where neoplastic epithelial cells grow in glandular patterns

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

pleomorphic adenoma

A

o Pleomorphic adenoma: all these elements arise from a single clone capable of giving rise to epithelial and myoepithelial cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

teratoma: two types?

A

contains recognizable mature or immature cells or tissues representative of more than one germ cell layer and sometimes all three
o originate from totipotential cells
o Mature teratoma, dermatoid cyst = benign teratoma = components are well differentiated
o Immature teratoma, teratocarcinoma = malignant teratoma = components are immature

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

hamartoma

A

disorganized but benign appearing masses composed of cells indigenous to the particular site
• ex. pulmonary chondroid harmatoma = islands of disorganized but histologically normal cartilage, bronchi and vessels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Squamous keratinocytes

A

Squamous keratinocytes: Squamous cell papilloma Squamous cell carcinoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Epidermal basal cells

A

Basal cell carcinoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

gland/duct epithelium

A

Adenoma Adenocarcinoma
Papilloma
Papillary carcinoma
Cystadenoma Cystadenocarcinoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

resp epithelium

A

Bronchial adenoma Bronchogenic carcinoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

renal tubule epithelium

A

Renal tubular adenoma Renal cell carcinoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

hepatocytes

A

Liver cell adenoma Hepatocellular carcinoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

transitional epithelium

A

Urothelial papilloma Urothelial carcinoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

placental epithelium

A

Hydatidiform mole Choriocarcinoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

testicular germ cells

A

Seminoma
Embryonal carcinoma
(both are malignant)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

skin,squamous mucosa (melanocytes)

A

Nevocellular nevus (benign) Malignant melanoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

fibroconnective CT

A

Fibroma Fibrosarcoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

adipose CT

A

Lipoma Liposarcoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Cartilage CT

A

Chondroma Chondrosarcoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
bone
Osteoma Osteogenic sarcoma
26
blood vessels
Hemangioma Angiosarcoma
27
lymph vessels
Lymphangioma Lymphangiosarcoma
28
synovium
malignant only | Synovial Sarcoma
29
mesothelium
only malignant | mesothelioma
30
Brain coverings
Meningioma | Invasive Meningioma
31
bone marrow
leukemia (malignant)
32
nodal/extranodal
lymphoma (malignant)
33
smooth muscle
Leiomyoma Leiomyosarcoma
34
striated mm.
Rhabdomyoma Rhabdomyosarcoma
35
anaplasia
lack of differentiation • malignant neoplasms that are composed of poorly differentiated cells are anaplastic • lack of differentiation is considered a hallmark of malignancy
36
pleomorphism
variation of size and shape of nuclei
37
metaplasia
replacement of one type of cell with another | • almost always found in assoc. w/ tissue damage, repair and regeneration
38
dysplasia
= disordered growth | • often occurs in metaplastic epithelium, but not all metaplasia is dysplastic
39
carcinoma in situ
when dysplastic changes involve entire thickness of epithelium but the lesion remains confined by the basement membrane and is a preinvasive neoplasm
40
3 things affecting rate of tumor growth?
o doubling time of tumor cells o growth fraction = fraction of tumor cells in the replicative pool- as tumors continue to grow, cells leave the proliferative pool due to shedding, lack of nutreints, necrosis, apoptosis and thus by the time tumor is clinically detectable, most cells are not in the proliferative pool o rate at which cells shed/divide
41
TIC's
• Tumor Initiating Cells: cells that allow a human tumor to grow and maintain itself indefinitely when transplanted into an immunodeficient mouse o like “leukemia stem cells” o TIC’s seem to be very common in some types of cancers o Tumors may have a small number of TIC’s that then “differentiate” to form the bulk of the tumor, while others are largely composed of TIC’s
42
fibrous capsule
benign tumors grow and expand slowly, thus they usually develop a rim of compressed CT around them o encapsulation doesn’t prevent tumor growth, but it keeps benign neoplasm as a discrete, readily palpable, easily movable mass o not all benign neoplasms are encapsulated – uterine leiomyomas have not capsule, but have well-defined cleavage planes
43
two exceptions to metastasis rule?
malignant neoplasms of glial cells in CNS (gliomas) and basal cell carcinomas are considered malignant but they DO NOT metastasize, and are locally invasive
44
lymphatic spread
most common in carcinomas • ex. breast in upper quadrant →axillary lymph nodes • ex. inner quadrant of breast → nodes along internal mammary aa. (infraclavicular and supraclavicular nodes) • ex. carcinomas of lung arising in major respiratory passages → perihlar tracheobronchial and mediastinal nodes
45
hematogenous spread: breast? bronchogenic? renal cell carcinoma? neuroblastoma?
***sarcomas – most lethal route! – go to brain, bone, liver and lung! * (liver and lungs are most frequently involved in dissemination) * cancers arising close to vertebral column often embolize through paravertebral plexus * ex. renal cell carcinoma: often invades branches of renal v. to grow in snakelike fashion up IVC * breast carcinoma → bone * bronchogenic carcinoma → adrenals and brain * neuroblastomas → liver and bones
46
renal cell carcinoma
renal V and IVC
47
hepatocellular carcinomas
portal radicles into vv.
48
adenocarcinoma of colon
liver via portal system
49
prostatic carcinoma
bone via vascular plexuses
50
small cell carcinomas of lung
adrenals and brain
51
lobular carcinoma of breast
CNS/meninges
52
breast carcinoma
bone
53
neuroblastoma
liver and bones
54
blue cell tumors
seen in infancy/childhood – neuroblastoma, Wilms tumor, retinoblastoma, acute leukemias, rhabdomyosarcomas
55
AD mutation of BRCA1/BRCA2
= breast cancer suscpetilbity • familal cancer = ovarian cancer
56
AD mutation of mutation of p16INK4a tumor suppressor
familal melanoma
57
AD mutation of Rb
1. Childhood Retinoblastoma: - due to mutation in RB tumor suppressor gene - children develop a retinoblastoma, increased chance of developing osteosarcoma
58
AD APC mutation
caused by mutation of adenomatous polyposis coli (APC) tumor suppressor gene. - develop innumerable polypoid ademoas of colon and develop colonic adenocarcinoma by age 50
59
AD p53 mutation
3. Li-Fraumeni syndrome: results from germiline mutations of p53 gene - not tissue specific
60
AD MEN-1 and RET mutation
Multiple endocrine Neoplasia types 1 and 2 (MEN-1 and MEN-2): mutation of genes that encode the menin txn factor and the RET tyrosin kinase respectively - MEN-1: pituitary, parathyroid, pancreas - MEN-2: thyroid, parathyroid, adrenals f
61
AD mutation of MSH2, MLH1, MSH6
Hereditary nonpolyposis colon cancer: caused by inactivation of a DNA mismatch repair gene * most common cancer predisposition syndrome o increases susceptibility to cancer of colon, small intestine, endometrium and ovary
62
AD mutation of PATCH
Nevoid basal cell carcinoma syndrome
63
AD mutatoin of NF1/NF2
Neurofibromatosis 1 and 2
64
chronic inflammation
o inflammatory GI diseases increase risk of cancer: ulcerative colitis, Helicobacter pylori gastritis, viral hepatitis, chronic pancreatitis o immune response may be maladaptive and may promote tumorigenesis o chronic inflammation may cause fixation of maladaptive mechanisms o ex. COX-2 is induced by inflammatory stimuli and is increased in colon cancers and other tumors
65
inflamm. bowel disease
colorectal carcinoma
66
chronic pancreatitis
- seen with alchoholics | - pancreatic carcinoma
67
Barret's esophagus
esophageal carcinoma
68
sjogren syndrome/hashimoto thyroiditis
MALT lymphoma
69
hetpatitis
hetpatocellular carcinoma
70
mononucleosis
B-cell non-Hodgkin lymphoma and Hodgkin lymphoma | - b/c of EBV
71
AIDS
Non-Hodgkin lymphoma, squamous cell carcinoma, Kaposi sarcoma - Because of Human immunodeficiency virus, human herpesvirus type 8
72
mid UV radiation
Malignant Melanoma Squamous Cell Carcinoma Basal Cell Carcinoma
73
ionizing radiation
Thyroid Carcinoma-Chernobyl | Leukemia - Hiroshima
74
cig. smoking
lung carcinoma
75
Helicobeter pylorii
gatric carcinoma
76
ethanol/cirrhosis
hepatocellular carcinoma
77
HPV 16,18
carcinoma uterine/cervix
78
30 y/o woman with atypical endometrial hyperplasia
endometrial adenocarcinoma
79
dysplastic bronchial mucosa
bronchogenic carcinoma
80
leukoplakia of oral cavity
squamous cell carcinoma
81
TGFA
prooncogene - overexpression of TGFalpha Astrocytomas, hepatocellular carcinomas
82
HGF
protooncogene ovexpression of HGF Thyroid cancer
83
ERBB1 (EGFR)
overexpression of EGF-receptor family (protooncogene) Squamous cell carcinoma of lung, gliomas
84
RET
protooncogene | point mutation causes leukemia
85
KRAS/HRAS/NRAS
PO pointmutation affects GTP-binding *** dyrsregulation of RAS/RAF/MAP pathway is linked with melanomas*** KRAS:Colon, lung, and pancreatic tumors HRAS: Bladder and kidney tumors NRAS: Melanomas, hematologic malignancies
86
ABL
PO | translocation causes chronic myeloid leukemia, acute lymphoblastic leukemia
87
BRAF
PO involved in RAS signal transduction | point mutation causes melanomas
88
C-MYC
PO, transcriptional activator translocation causes burkitt's lymphoma
89
N-MYC
PO, transcriptional activator amplification causes Neuroblastoma, small-cell carcinoma of lung
90
L-MYC
PO, txn activator | amplification causes small-cell carcinoma of the lung
91
Cyclin D
PO, translocation causes mantle cell lymphoma amplification causes breast and esophageal cancers
92
Cyclin E
PO overexpression causes breast cancers
93
CDK4
PO - amplification of point mutation Forms a complex with cyclin D that phosphorylates RB, allowing the cell to progress through the G 1 restriction point. glioblastoma, melanoma and sarcomas
94
RAS mechanism
point mutation of the RAS family genes I sthe single most common abnormality of proto-oncogenes in human tumors • Oncogene • Ras plays role in signaling cascade, resulting in mitogenesis • it is activated by growth factor binding at PM • RAS proteins flip back forth b/w excited and quiescent state o recycling occurs through nucleotide exchange (GDP to GTP) which activates protein • Catalyzed by guanine nucleotide releasing proteins o GTP hydrolysis → GDP to inactivate • Catalysed GTPase activity via GTPase-activating proteins (GAPs): act as “brakes” • inactived RAS = RAS + GDP • Activated RAS = RAS + GTP • Activated RAS stimulates mitogen-activated protein (MAP)
95
amatinib mesylate
drug that inhibits BCR-ABL kinase
96
mechanism of MYC
* oncogene * MYC interacts with components of DNA-replication machinery and plays a role in selection of origins of replication. * overexpression may drive activation of more origins than needed for normal cell division, * MYC can act to reprogram somatic cells into pluripotent stem cells * Dysregulation of MYC resulting from translocation of gene results in Burkitt Lymphoma – B cell tumor
97
Cyclins and CDK's
* CDK-cyclin complexes phosphorylate crucial target proteins that drive the cell through the cell cycle * mutations result in increased activity of cyclins and CDKs favoring proliferation * cyclincs bind CDKs and intiate cell proliferation
98
what are CDKI's?
* CIP/WAF family: p21, p27, p57 * INK4 family: p16, p16, p18 * expression of these inhibitors is down-regulated by mitogenic signaling pathways thus promoting the progression of cell cycle
99
CDK2
Forms a complex with cyclin E in late G 1, which is involved in G 1/S transition. Forms a complex with cyclin A at the S phase that facilitates G 2/M transition.
100
CDK1
Forms a complex with cyclin B that facilitates G 2/M transition.
101
p21, p27
Block the cell cycle by binding to cyclin-CDK complexes; p21 is induced by the tumor suppressor p53; p27 responds to growth suppressors such as TGF-β.
102
INK4/ARF family
p16/INK4a binds to cyclin D–CDK4 and promotes the inhibitory effects of RB; p14/ARF increases p53 levels by inhibiting MDM2 activity.
103
p53 main fn.
Tumor suppressor gene altered in the majority of cancers; causes cell cycle arrest and apoptosis. Acts mainly through p21 to cause cell cycle arrest. Causes apoptosis by inducing the transcription of pro-apoptotic genes such as BAX. Levels of p53 are negatively regulated by MDM2 through a feedback loop. p53 is required for the G 1/S checkpoint and is a main component of the G 2/M checkpoint.
104
TGF-beta receptor
TS Growth inhibition somatic mutations: Carcinomas of colon
105
E-cadherin
TS FN; cell adhesion SM: carcinoma of stomach IM: familal gastric cancer
106
NF1
TS FN: Inhibition of RAS signal transduction and of p21 cell cycle inhibitor SM: neuroblastomas IM: Neurofibromatosis type 1 and sarcomas, optic nerve gliomas
107
NF2
TS fn: cytoskeletal stability SM: Schwannomas and meningiomas IM: Neurofibromastosis type 2, acoustic schwannomas, and meningiomas
108
APC/β-catenin
TS fn: inhibition of signal transdution SM: Carcinomas of stomach, colon, pancreas; melanoma IM: Familial adenomatous polyposis coli/colon cancer
109
PTEN
TS: Fn: PI1 kinase signal transduction SM: endometrial and prostate cancers IM: Cowden syndrome
110
SMAD2 SMAD4
TS Fn:TGF-β signal transduction SM: colon, pancreas tumors
111
RB1
TS Fn: regulation of cell cycle SM: Retinoblastoma; osteosarcoma carcinomas of breast, colon, lung IM: Retinoblastomas, osteosarcoma
112
p53
TS Fn: Cell cycle arrest and apoptosis in response to DNA damage SM; most human cancers IM: Li-Fraumeni syndrome; multiple carcinomas and sarcomas
113
WT1
TS Fn: nuclear txn SM/IM: Wilm's tumor
114
p16/INK4a
TS fn: Regulation of cell cycle by inhibition of cyclin-dependent kinases SM: Pancreatic, breast, and esophageal cancers IM:Malignant melanoma
115
BRCA1/BRCA2
fn: dna repair IM: Carcinomas of female breast and ovary; carcinomas of male breast
116
two hip hypothesis
* two mutations are required to eliminate tumor suppressor genes * in familial cases: one gene is inherited, the other spontaneously mutates * in sporadic cases: both genes must mutate * Thus heterozygosity of the RB gene does not affect cell behavior loss of heterozygosity: when the cell loses both of its normal alleles, it results in loss of the gene
117
mechanism of RB
• exists in an active hypophosphorylated state in quiescent cells and in an inactive hyperphosphorylated state in G1/S transition (most important checkpoint) - if RB is hypophos. then it remains bound to E2F, and E2F cannot signal txn (RB can be hypophos. via Ggrowth inhibitors stimulated CDKI's) - RB is hyperphsophorylated via Growth factors (EGF, PDGF) stimulated cyclins D/E, resulting in release of E2F and transcriptional activity *note HPV is known to inactivate RB protein
118
Li-Fraumeni syndrome
mutation in p53: results in increases in malignant tumors – sarcomas, breast cancer, leukemia, brain tumors, carcinomas of arenal cortex
119
MDM2/MDMX
stimulate the degredation of p53, and are often overexpressed in malignancies where p53 is not mutated
120
APC/β Catenin Pathway:
* adenomatous polyposis coli genes represent tumor suppressors that down-regulate growth promotic receptors. * germline mutations result in thousands of adenomatous polyps in colon during teens to 20’s * usually polyps will undergo transformation giving rise to colonic tumors * APC dowregulates B-catenin in the absence of WNT signaling, preventing Beta catenin to accumulate in the cytoplasm * WNT triggered, inhibits APC, allowing B-Catenin build up, resulting in increase in c-myc and cyclinD. * cells with loss of APC behave as if under continuous WNT signaling * Beta-Catenin binds E-Cadherin (cell surface protein that maintains intercellular adhesiveness) – loss of cellular contact allows B-Catenin to stimulate proliferation = contact inhibited
121
contact inhibition
• Beta-Catenin binds E-Cadherin (cell surface protein that maintains intercellular adhesiveness) – loss of cellular contact allows B-Catenin to stimulate proliferation
122
anoikis
loss of adhesion to BM, can trigger apoptosis
123
BCL2
ovexpression leads to tumors due to loss of apoptosis
124
angiogenesis
• bFGF and VEGF
125
bavacizumab
anti-VEGF Ab used for treatment
126
MMPs
** overexpression of MMPs has been implicated in many tumors proteases that have been implicated in tumor invasion. MMP’s regulate tumor invasion not only by remodeling insoluble compnents of BM but also by releasing ECM-sequestered growth factors o breakdown products of collagen have a chemotactic and angiogeneic and growth promoting effects o MMP9 = gelatinase that cleaves collagen type IV
127
CD44
adhesion molecule: expressed on normal T lymph. is used by tumors to migrate to selective sites in lymphoid tissue o overexpression of CD44 may favor metastatic spread
128
CXCR4 and CCR7
chemokines that are expressed --> in some breast cancers --> allow for metastasis to lymph nodes
129
Hereditary nonpolyposis colon cancer syndrome:
Hereditary nonpolyposis colon cancer syndrome: • results from defects in genes involvedin DNA mistmatch repair – results in creation of microsatellites, causing microsatellite instability • familial carcinomas of the colon
130
xeroderma pigmentosum
* defective DNA excision repair * UV radiation causes crosslinking of pyrimidine residues, and lacks excision repair * increased development of cancers of the skin, especially after exposure to sunlight
131
bloom syndrome
• defect in DNA repair by homologous recombination
132
BRCA1/BRCA2
* breast cancers * cells lacking these genes have been shown to associate with a variety of proteins involved in homologous recombination repair pathway
133
warburg effect
* cancer cells shift to aerobic glycolysis * aerobic glycolysis allows tumors to need less O2 supplied by blood * HIF1alpha downregulates genes involved in ox phos * decreased demand by tumor cells increases the O2 supply, allowing for increased number of tumor cells that can be supported by the vasculature * halting of breakdown from glucose to pyruvate allows these carbons to be shunted to anabolic pathway and thus used for building blocks for cell division * LKB1: tumor suppressor gene that halts anabolic metabolism
134
Burkitt Lymphoma
c-MYC overexpression of proto-oncogene due to translocation o MYC is translocated to IGH sequence t(8:14)(q24;q32) and thus loses its regulatory sequence o IGH is highly expressed in B cell precursors
135
BCR-ABL
• Philidelphia chromosome: o fusion of genes from 9 and 22 forming BCR-ABL gene o characteristic of CML and acute lymphoblastic leukemias
136
ERBB2
protooncogene | gene amplification often leading to breast cancer
137
VHL
tumor suppresor - silenced in renal cell carcinomas
138
miRNAS
* mediate post transcriptional gene silencing through RNA-induced silencing complex * by negatively regulating BCL2 (anti-apoptotic protein), miRNAs behave as tumor suppressor genes
139
CYP1A1
• ex. cigarette smoke: metabolized by the P-450 gene, CYP1A1 – smokers with this genotype are more susceptible to lung cancer
140
HTLV-1
Human T cell Leukemia Virus Type 1: (HTLV-1) - • causes a form of T-cell leukemia/lymphoma (seen in Japan and carribean) • affects CD4+ T cells • contains protein tax that stimulates txn of viral mRNA by acting on 5’ terminal repeat: it inactivates inhibitor p16/INK4a and enhances cyclin D activation. tax also activates NF-kb • HTLV-1 causes expansion of nonmalignant polyclonal cell population through stimulatory effects of Tax – the proliferating T cells are at increased risk of mutations and genomic instability induced by Tax, allowing mutations to accumulate and eventually a monoclonal neoplastic T-cell population emerges
141
HPV
– type 16 and 18 – cause squamous cell carcinoma of cervix and anogenital region • cells in which viral genome is integrated have moregenomic instability, integration interrupts the viral DNA within the E1/E2 open reading frame, leadig to loss of E2 viral repressor, and overexpression E6/E7 oncoproteins.
142
E7
binds to the Rb protein and displaces E2F txn factor – promoting progression through cell cycle. E7 also inactivates CDKI’s p21 and p27.
143
E6
has higher affinity for p53 and blocks p53, thus disabling apoptosis
144
EBV
• Burkitt-Lymphoma: B-cell lymphoma, Hodgkin lymphoma, nasopharyngeal and gastric carcinomas, rare forms or T cell lymphomas and NK lymphomas o except for nasopharyngeal carcinoma, all others are B-cell tumors • EBV infects B lymphocytes using the CD21 receptor to attach and infect B cells • LMP-1: latent membrane protein 1, acts as an oncogene and acts on CD40 receptor, activating the NF-kb pathway and JAK/STAT signaling, causing B-cell survival and proliferation o also activates BCL2, prevening apoptosis • Burkitt lymphoma: neoplasm of B lympohcytes that is most common childhood tumor in central Africa and New Guinea o in regions of world where Burkitts is endemic, concomitatnt infections such as malaria impaire immune competence, allowing sustained B cell proliferation.
145
Hep B and Hep C
* close association with HBV infection and liver cancer – Hepatocelluar carcinomas * dominant effect seems to be immunologically mediated chronic inflammation with hepatocyte death leading to regeneration and genomic damage * chronic viral infection leads to compensatory proliferation of hepatocytes * Activation of the NF-kB pathway w/in hepatocytes blocks apoptosis, allowing dividing hepatocytes to incur genotoxic stress and accumulate mutations
146
H. pylori
• bacterium that causes gastric adenocarcinomas and gastric lymphomas o MALTomas = mucous associated lymphoid tissue • involves increased epithelial cell proliferation in a background of chronic gastric inflammation (similar to viral hep)
147
tumor ags recognized by CD8 T cells?
DNA viruses: HPV and EBV
148
antitumor effector cells?
• CTL’s are effective against virus-associated neoplasms: important against HPV, EBC ``` • NK cells: capable of destroying tumor cells without prior sensitization – thus may provide first line defense o tumors that don’t express MHC I class Ags cannot be recognized by T cells, these may however trigger NK cells which are normally inhibited by recognition of normal class I molecules ```
149
AIDS cancers
non-hodgking lymphoma (50%), primary CNS lymphoma, Kaposi sarcoma, cervical neoplasia
150
cushing syndrome
Cushing Syndrome: ** very common** • results from small-cell carcinoma of lung • ACTH is secreted in xs – see elevated corticotropin levels
151
hypercalcemia
Hypercalcemia: ** very common** • seen with squamous cell carcinomas of lung • Release of PTH or PTH related proteins: TGFalpha, TNF, IL-1 • may also be seen with osteolytic cancers such as osteosarcomas, multiple myeloma, metastatic bone lesions
152
SIADH
Syndrome of Inappropriate ADH secretion: | • seen with small cell carcinoma of lung
153
Nonbacterial thrombotic endocarditis | •
Nonbacterial thrombotic endocarditis • seen with advanced cancers – i.e. mucin secreting adenocaricnomas • results in hypercoagulability
154
acanthosis nigricans
gray black patches of hyperkeratosis on the skin • gastric carcinoma, lung carcinoma, uterine carcinoma • immunological causes; results in secretion of EGF
155
hypertrophic osteoarthropathy
• seen in 1-10% of patients with bronchogenic carcinomas characterized by o periosteal new bone formation, at distal ends of long bones, fingers o arthritis of adjacent joints o clubbing of digits
156
grading v. staging
Grading: based on degree of differentiation, and in some cancers the number of mitoses or architectural features – Typically established by the pathologist – How differentiated is the tumor? Other factors affecting or mitigating? Staging: based on size of primary lesion, extent of spread to reginal lymph nodes, presence or absence of blood-borne metastases – Typically established by the oncologist (although ‘contributed to [depending on the malignancy] by the pathologist’ – How widely spread is the cancer? TNM factors. – T= tumor, N=Lymph node, M=Metastases
157
prevalence vs. incidence
Prevalence: Total cases in defined population on a specified date (e.g., Jan 1, 2007); Prevalence represents both new and all pre-existing cases alive on a certain date enumerated by one of these three possible methods of expression: An absolute number (e.g., total cases in US) Expressed as % population (Total cases in population as %) Number cases/100,000 population at the specified date ``` Incidence: New cases diagnosed during specified time (usually a year) for given population (100,000 unit often used) Incidence reflects only new cases during a defined time. # new cases/100,000 population/year ```
158
patients with multiple myeloma
gG kappa is seen most commonly in patients with multiple myeloma on electrophoresis
159
TdT
primitive B cell marker
160
Beta2 microglobulin
primitive B cell marker | - lymphoid malignancies: B-cell chronic lymphocytic leukemia, non-Hodgkin Leukemia, multiple myeloma
161
PSA vs. Her2
PSA is organ-specific but not cancer-specific, whereas HER2/ neu is cancer-specific but not tissue-specific and is found to be increased in breast cancers, as well as lung and other epithelial cell tumors.
162
CEA
carcinoembryonic Ag - tumor marker for GI cancer: but also elevated in adenocarcinomas of breast, lung, liver cancers - used to only be for colon cancer
163
CA-19-9
gastric cancer, pancreatic cancer, colon cancer
164
CA 125
marker for ovraian cancers
165
Cytokeratin 19 fragment (CYFRA 21-1)
breast cancer and squamous cell carcinoma of lung
166
HcG
elevated in trophoblastic tumors and choriocarcinomas of females elvated in seminomatous testicular tumors in males
167
AFP
alpha feto protein | - hepatocellular carcinoma and germ cell tumors of testis
168
PTH-RP
Parathyroid Hormone-Related Peptide Plasma concentrations of parathyroid hormone-related peptide (PTH-RP) are elevated in the majority of patients with cancer-associated hypercalcemia. secreted by tumors associated with hypercalcemia.
169
calcitonin
medullary carcinoma of thryoid
170
metanephrine
pheochromocytoma
171
PSA
prostate cancer
172
CA-15-3
breast cancer
173
CA72-4
gstric carcinoma
174
Her2-/neu
breast cancer
175
p53, APC, RAS mutants in stool and serum
colon cancer
176
p53 and RAS mutants in stool and serum
pancreatic cancer
177
p53 and RAS mutants in sputum and serum
lung cancer
178
p53 mutants in urine
bladder cancer